Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma
The purpose of this study is to compare the efficacy and safety of cisplatin (CDDP) and epirubicin (EPI) in the treatment of transcatheter chemoembolization for Hepatocellular Carcinoma (HCC).
Carcinoma, Hepatocellular
DRUG: epirubicin|DRUG: Cisplatin
response rate, 6 months
The purpose of this study is to compare the efficacy and safety of cisplatin (CDDP) and epirubicin (EPI) in the treatment of transcatheter chemoembolization for Hepatocellular Carcinoma (HCC).